Argenx Se (ARGX) Shares Outstanding (2015 - 2026)
Argenx Se's (ARGX) quarterly Shares Outstanding (Entity) came in at $147.7 million in Q2 2026, up 1.89% YoY from $145.0 million in Q2 2025, and little changed on a QoQ basis from $147.4 million in Q1 2026.
Argenx Se (ARGX) Shares Outstanding (2015 - 2026) Analysis & Trends
Argenx Se (ARGX) has 12 years of Shares Outstanding (Entity) data on file, last reported at $147.7 million in Q2 2026.
- Quarterly Shares Outstanding (Entity) rose 1.89% year-over-year to $147.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $147.7 million (up 1.89% YoY) and the FY2025 annual result came in at $145.6 million, up 2.41% from the prior year.
- Shares Outstanding (Entity) steadied at $147.7 million in Q2 2026, from $147.4 million in the prior quarter.
- In the past five years, Shares Outstanding (Entity) ranged from a high of $147.7 million in Q2 2026 to a low of $123.7 million in Q1 2022.
- A 5-year average of $138.4 million and a median of $141.0 million in 2024 frame the typical range for Shares Outstanding (Entity).
- Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) rose 7.26% — and 2026, when it grew 1.76%.
- Tracing ARGX's Shares Outstanding (Entity) over 5 years: stood at $129.2 million in 2022, then rose by 5.13% to $135.8 million in 2023, then rose by 4.7% to $142.2 million in 2024, then gained by 2.41% to $145.6 million in 2025, then gained by 1.45% to $147.7 million in 2026.
- The last three Shares Outstanding (Entity) figures came in at $147.7 million (Q2 2026), $147.4 million (Q1 2026), and $145.6 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 62.19 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 210.89 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.45 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 25.05 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 445.06 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 133.61 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 217.35 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 720.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 62.19 Mn |
| Mar 31, 2026 | 62.06 Mn |
| Dec 31, 2025 | 61.30 Mn |
| Sep 30, 2025 | 61.37 Mn |
| Jun 30, 2025 | 61.03 Mn |
| Mar 31, 2025 | 60.98 Mn |
| Dec 31, 2024 | 59.86 Mn |
| Sep 30, 2024 | 60.09 Mn |
| Jun 30, 2024 | 59.40 Mn |
| Mar 31, 2024 | 59.31 Mn |
| Dec 31, 2023 | 57.17 Mn |
| Sep 30, 2023 | 58.13 Mn |
| Jun 30, 2023 | 55.69 Mn |
| Mar 31, 2023 | 55.56 Mn |
| Dec 31, 2022 | 54.38 Mn |
| Sep 30, 2022 | 55.20 Mn |
| Jun 30, 2022 | 53.45 Mn |
| Mar 31, 2022 | 52.08 Mn |
| Dec 31, 2021 | 51.08 Mn |
| Sep 30, 2021 | 51.47 Mn |